← Back to Search

Sodium Channel Blocker

Ranolazine for Coronary Artery Disease (REMS Trial)

Phase 4
Waitlist Available
Led By Narendra Singh, MD
Research Sponsored by Atlanta Heart Specialists, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 6 months
Awards & highlights

REMS Trial Summary

The purpose of this study is to measure the effect of ranolazine on ETT (exercise treadmill test) exercise duration in four ethnic subgroups with established coronary artery disease and risk factor(s) for the metabolic syndrome: Caucasian, African American, Southeast Asian and East Indian.

Eligible Conditions
  • Coronary Artery Disease
  • Metabolic Syndrome
  • Angina

REMS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Exercise Duration
Secondary outcome measures
Angina Pectoris
Pharmaceutical Preparations
HgbA1c
+2 more

REMS Trial Design

2Treatment groups
Active Control
Group I: Standard of CareActive Control1 Intervention
Group II: RanolazineActive Control1 Intervention
Ranolazine in addition to standard of care medical therapy

Find a Location

Who is running the clinical trial?

Atlanta Heart Specialists, LLCLead Sponsor
Gilead SciencesIndustry Sponsor
1,083 Previous Clinical Trials
843,199 Total Patients Enrolled
18 Trials studying Coronary Artery Disease
8,744 Patients Enrolled for Coronary Artery Disease
Narendra Singh, MDPrincipal InvestigatorAtlanta Heart Specialists, LLC
2 Previous Clinical Trials
112 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ranolazine, Ethnicity and the Metabolic Syndrome
Narendra Singh, MD 2011. "Ranolazine, Ethnicity and the Metabolic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01304095.
All > Osteopenia > Ranolazine
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top